Choose Language
Select a language for news translation.
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent …
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE: LLY ) ranks among the most profitable blue chip stocks to …
Jordi Visser argues Eli Lilly's AI infrastructure, proprietary metabolic data, and GLP-1 drugs could make it the world's largest company within 5 years. Lilly…
Written by Joe Tenebruso for The Motley Fool -> Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace w…
Two drugs make up nearly two-thirds of Eli Lilly 's (NYSE: LLY) top line, generating around $12.8 billion in revenues in the first quarter of 2026. The two dru…
Written by Reuben Gregg Brewer for The Motley Fool -> Eli Lilly is probably best known for its dominant GLP-1 drugs right now. The company's recent $3.8 bill…
Written by Jeff Siegel for The Motley Fool -> Eli Lilly now controls roughly 60% of the GLP-1 market. International growth could become Lilly's next major ca…
Written by Reuben Gregg Brewer for The Motley Fool -> Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nor…
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly has worked hard to diversify its pipeline. Three new acquisitions will further help decreas…
One of the biggest misconceptions about ETFs is that they are highly diversified “baskets” of stocks. Sometimes they are. But as the iShares US Pharmaceuticals…
